ORIC Pharmaceuticals, Inc. (ORIC) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $12.69, ORIC has negative trailing earnings (P/E not meaningful) and an ROE of -35.35%. Market capitalisation stands at $1.3B.
Balance sheet quality for ORIC: current ratio of 14.1, net cash position of $269.9M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $12.69 |
| Market Cap | $1.3B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.45 |
| EV / EBITDA | -8.81 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -35.35% |
| Return on Invested Capital | -40.32% |
| Return on Assets | -34.68% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 13.19 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 13.45 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ORIC | ORIC Pharmaceuticals, Inc. | $1.3B | 3.45 | -35.4% | |
| ELVN | Enliven Therapeutics, Inc. | $3.5B | |||
| RLAY | Relay Therapeutics, Inc. | $4.1B | 4.29 | -48.8% | |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.6B | |||
| PGEN | Precigen, Inc. | $2.4B | 57.33 | -498.3% | |
| ATAI | Atai Beckley Inc. | $2.7B | 10.53 | -366.5% |
Price Performance
| 1 month | -8.55% |
| 3 months | +49.94% |
| Year-to-date | +55.62% |
| 1 year | +21.01% |
| 3 years | +52.82% |
52-Week Range
| 52-week High | $14.93 |
| 52-week Low | $7.23 |
| Avg Volume (90d) | 1.6M |
Related companies: AMLX · ATAI · ELVN · INBX · NKTR · PGEN · RLAY
Explore sector: Healthcare · Biotechnology
More sections of ORIC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks